FDA Alerts

The FDA has approved the first generic of naloxone hydrochloride nasal spray for the treatment of opioid overdose. The new option is intended for use by individuals without medical training.

The FDA has cleared for marketing the first medical device for the treatment of attention-deficit/hyperactivity disorder

The FDA has approved a new treatment option for adults with body mass index (BMI) of 25-40 kg/m2.

The FDA has approved a new option for the treatment of osteoporosis in postmenopausal women who have a high risk of fracture.

After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.

Following a clinical trial testing its safety and efficacy, the FDA has approved a new oral treatment for patients with relapsing forms of multiple sclerosis.

After the clinical trial showed positive results, the first treatment option for adults with inflammatory arthritis in the spine has been approved.

The FDA has approved a new option for the treatment of men with certain forms of hypogonadism caused by specific medical conditions.

The new oral treatment for multiple sclerosis is indicated for patients with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.